The 7 major paranasal sinus diseases markets are expected to exhibit a CAGR of 4.3% during 2024-2034.
Report Attribute
|
Key Statistics
|
---|---|
Base Year
|
2023
|
Forecast Years
|
2024-2034
|
Historical Years
|
2018-2023
|
Market Growth Rate 2024-2034 | 4.3% |
The paranasal sinus diseases market has been comprehensively analyzed in IMARC's new report titled "Paranasal Sinus Diseases Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Paranasal sinus diseases refer to various medical conditions that affect the paranasal sinuses, which are a group of air-filled cavities located within the bones surrounding the nose. These sinuses play a crucial role in producing mucus, which helps to humidify and filter the air we breathe. However, when the sinuses become inflamed or infected, they can lead to multiple health issues, like brain abscesses. Some common symptoms of the ailments include difficulty in breathing, a dull, aching sensation or pressure around the eyes, forehead, and cheeks, headache, excess mucus production, runny or stuffy nose, facial tenderness, loss of smell, altered sense of taste, cough, fatigue, fever, etc. The diagnosis of these diseases typically involves a combination of medical history assessment, clinical feature evaluation, and physical examination. The healthcare provider will also perform an endoscopy, in which a flexible tube with a light and camera may be inserted into the nasal passages to visualize the sinuses directly and identify any abnormalities. Numerous imaging techniques, like magnetic resonance imaging, computed tomography scans, X-rays, etc., are further utilized to detect the underlying cause of the conditions.
The rising cases of bacterial, viral, or fungal infections, which can result in inflammation and swelling of the nasal passage, are primarily driving the paranasal sinus diseases market. In addition to this, the increasing prevalence of anatomical abnormalities that affect the production of mucus, leading to thickened secretions in the respiratory system, is also creating a positive outlook for the market. Moreover, the widespread adoption of nasal corticosteroid sprays, since they help to reduce inflammation in the nasal passages and sinuses, as well as relieve congestion and symptoms in patients, is further bolstering the market growth. Apart from this, the inflating application of immunotherapy that desensitize the immune system to specific allergens and minimize the severity of allergic reactions is acting as another significant growth-inducing factor. Additionally, the emerging popularity of functional endoscopic sinus surgery, owing to its numerous advantages, such as minimal invasiveness, faster recovery, and fewer complications compared to traditional open procedures, is expected to drive the paranasal sinus diseases market during the forecast period.
IMARC Group's new report provides an exhaustive analysis of the paranasal sinus diseases market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for paranasal sinus diseases and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the paranasal sinus diseases market in any manner.
Time Period of the Study
Countries Covered
Analysis Covered Across Each Country
This report also provides a detailed analysis of the current paranasal sinus diseases marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Late-Stage Pipeline Drugs
Drugs | Company Name |
---|---|
FLONASE (Fluticasone Propionate) | GlaxoSmithKline |
Dupixent (Dupilumab) | Regeneron/Sanofi |
Nucala (Mepolizumab) | GlaxoSmithKline |
Zithromax (Azithromycin) | Pfizer |
LYR-210 | Lyra Therapeutics |
Tezpire (Tezepelumab) | Amgen/AstraZeneca |
*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.
Market Insights
Epidemiology Insights
Paranasal Sinus Diseases: Current Treatment Scenario, Marketed Drugs and Emerging Therapies